FDA Drug Approvals
Printable Version   Email to a friend

Myozyme Approved - Genzyme Corp. - Treatment for Pompe Disease

Myozyme is a recombinant formulation of the human enzyme acid alpha-glucosidase (GAA) indicated for use in patients with Pompe disease (GAA deficiency), a debilitating and often fatal muscle disorder.

Related Articles:

Genzyme Provides Update on U.S. Marketing Application for Myozyme - January 17, 2006

Genzyme Submits BLA for Myozyme for Treatment of Pompe Disease - July 29, 2005

Latest FDA Drug Approvals...

FDA Drug Approvals Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec

More News Resources


MedNotes
Advertisement